Rinri Therapeutics · Cell Therapy · Phase 1/2
ActiveTherapeuticStronger sources
Population
Adults · 18–74 years
Cochlear-implant candidates with presbycusis or auditory neuropathy
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing LossAuditory Neuropathy

